is allulose a glp 1 agonist GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose GLP-1 and Anesthesia: Considerations and

These data were arranged as follows: (1) study characteristics, such as study ID, study design, country, population, main inclusion criteria, intervention and control measures (name, number in the group, Route of administration, and regimen), and primary endpoints

Severe gastrointestinal disease, particularly gastroparesis, may alter both efficacy and tolerability and requires careful consideration

When used in conjunction with diet and exercise, it can lead to significant weight loss which in turn reduces the incidence of diabetes, hypertension and reduces the risk of cancer

Factors such as individual metabolism, commitment to lifestyle adjustments, and overall health status play a critical role in determining how effective either medication will be for a particular person

doi: 10.1016/j.metabol.2019.154045

Dipeptidyl peptidase 4 inhibition may facilitate healing of chronic foot ulcers in patients with type 2 diabetes